Julio Schwarz, MD
Cardiovascular Disease · Fort Smith, ARNPI 1699779314
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,595 of the $69,702 with a category attached, or 88.4%. 25 manufacturers reported payments, led by Novartis at 39.6% of the total. Reporting peaked in 2019 at $44,025 and has fallen 97.7% since, to $1,032 in 2025. Among cardiovascular disease clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 425 payments — averaging $164.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$28K
- Amgen$26K
- Amarin Pharma, Inc.$6K
- Boehringer Ingelheim$6K
- Johnson & Johnson$907
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$599
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$61,59588%
- Travel & lodging$1,9143%
- Food & beverage$6,1109%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 58 | $27,637 |
| Amgen | 109 | $26,261 |
| Amarin Pharma, Inc. | 9 | $6,285 |
| Boehringer Ingelheim | 32 | $6,257 |
| Johnson & Johnson | 69 | $907 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 45 | $599 |
| Merck | 24 | $410 |
| Medtronic(2 entities) | 15 | $227 |
| Regeneron Healthcare Solutions, Inc. | 6 | $184 |
| AstraZeneca | 10 | $160 |
| Pfizer | 12 | $159 |
| E.r. Squibb & Sons, L.L.C. | 8 | $117 |
| Kestra Medical Technology Services, Inc. | 4 | $96 |
| Esperion Therapeutics, Inc. | 4 | $70 |
| Alnylam Pharmaceuticals Inc. | 4 | $68 |
| Bridgebio Pharma, Inc. | 3 | $49 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Bayer | 2 | $32 |
| Philips North America LLC | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $23 |
| Edwards Lifesciences | 1 | $22 |
| Abiomed | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Novo Nordisk | 1 | $20 |
| Biotronik Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$69,702 in reported general payments places this provider in the 95th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,558 | $1,223,078 |
| EntrestoSacubitril/Valsartan | 849 | $848,024 |
| FarxigaDapagliflozin Propanediol | 705 | $538,588 |
| Repatha SureclickEvolocumab | 560 | $331,127 |
| XareltoRivaroxaban | 223 | $183,327 |
| CamzyosMavacamten | 15 | $126,464 |
| JardianceEmpagliflozin | 142 | $116,794 |
| Praluent PenAlirocumab | 85 | $40,415 |
| Ranolazine ErRanolazine | 506 | $35,477 |
| Sildenafil Citrate | 62 | $25,253 |
| VascepaIcosapent Ethyl | 50 | $22,706 |
| BrilintaTicagrelor | 33 | $18,828 |
| Nifedipine ErNifedipine | 655 | $11,075 |
| VerquvoVericiguat | 15 | $9,117 |
| Nebivolol Hcl | 207 | $9,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $159 | $1,223,0781,558 claims |
| NovartisEntresto | $27,637 | $848,024849 claims |
| AstraZenecaFarxiga, Brilinta | $160 | $557,416738 claims |
| Johnson & JohnsonXarelto | $907 | $183,327223 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $117 | $126,46415 claims |
| Boehringer IngelheimJardiance | $6,257 | $116,794142 claims |
| MerckVerquvo | $410 | $9,11715 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $23 | $2,10412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Fort Smith
- Abdul-Nasser AdjeiFort Smith$26K
- Robert ParrisFort Smith$13K
- Ian CawichLittle Rock$294K
- Barry TedderJonesboro$130K
- Harvinder DodEl Dorado$126K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Maximiliano ArroyoJonesboro$46K
- Wesley LaneLittle Rock$46K
- Omar QaqishLittle Rock$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.